340
Lysik MA, Wu-Pong S (2003) Innovations in oligonucleotide drug delivery. J Pharm Sci
92:1559–1573. https://doi.org/10.1002/jps.10399
Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, Anraku M, Hirayama
F, Uekama K, Otagiri M (2010) Evaluation of carboxymethyl-β-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int J
Pharm 397:1–8. https://doi.org/10.1016/j.ijpharm.2010.06.018
Maestrelli F, González-Rodríguez ML, Rabasco AM, Mura P (2005) Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug
delivery. Int J Pharm 298:55–67. https://doi.org/10.1016/j.ijpharm.2005.03.033
Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ (2006) A new drug nanocarrier consisting
of chitosan and hydroxyl propyl cyclodextrin. Eur J Pharm Biopharm 63:79–86. https://doi.
org/10.1016/j.ejpb.2005.12.006
Maestrelli F, González-Rodríguez ML, Rabasco AM, Ghelardini C, Mura P (2010) New “drugin cyclodextrin-in deformable liposomes” formulations to improve the therapeutic efficacy of
local anaesthetics. Int J Pharm 395:222–231. https://doi.org/10.1016/j.ijpharm.2010.05.046
Mahmoud AA, El-Feky GS, Kamel R, Awad GEA (2011) Chitosan/sulfobutylether-β-cyclodextrin
nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413:229–236.
https://doi.org/10.1016/j.ijpharm.2011.04.031
McCormack B, Gregoriadis G (1994a) Drugs-in-cyclodextrins-in liposomes: a novel concept in
drug delivery. Int J Pharm 112:249–258. https://doi.org/10.1016/0378-5173(94)90361-1
McCormack B, Gregoriadis G (1994b) Entrapment of cyclodextrin-drug complexes into
liposomes: potential advantages in drug delivery. J Drug Target 2:449–454. https://doi.
org/10.3109/10611869408996821
McCormack B, Gregoriadis G (1996) Comparative studies of the fate of free and liposomeentrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats:
implications in drug delivery. Biochim Biophys Acta 1291:237–244. https://doi.org/10.1016/
S0304-4165(96)00096-7
Memişoğlu E, Bochot A, Özalp M, Sen M, Duchêne D, Hincal A (2003) Direct formation of
nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res 20:117–125.
https://doi.org/10.1023/A:1022263111961
Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA (2005) Tamoxifen citrate loaded
amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J Control
Release 104:489–496. https://doi.org/10.1016/j.jconrel.2005.03.006
Méndez-Ardoy A, Guilloteau N, Di Giorgio C, Vierling P, Santoyo-González F, Ortiz Mellet C,
García Fernández JM (2011) β-cyclodextrin-based polycationic amphiphilic “click” clusters:
effect of structural modifications in their DNA complexing and delivery properties. J Org Chem
76:5882–5894. https://doi.org/10.1021/jo2007785
Mennini N, Cirri M, Maestrelli F, Mura P (2016) Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin:
effect of cyclodextrin complexation. Int J Pharm 515:684–691. https://doi.org/10.1016/j.
ijpharm.2016.11.013
Merkus FWHM, Verhoef JC, Romeijn SG, Schipper NGM (1991) Absorption enhancing effect of
cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588–592. https://doi.
org/10.1023/A:1015896405389
Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, Van Der Kuy PHM, Hermens WAJJ,
Schipper NGM (1999) Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36:41–57.
https://doi.org/10.1016/S0169-409X(98)00054-4
Messner M, Kurkov SV, Jansook P, Loftsson T (2010) Self-assembled cyclodextrin aggregates and
nanoparticles. Int J Pharm 387:199–208. https://doi.org/10.1016/j.ijpharm.2009.11.035
Mrówczyński R, Jędrzak A, Szutkowski K, Grześkowiak BF, Coy E, Markiewicz R, Jesionowski T,
Jurga S (2018) Cyclodextrin-based magnetic nanoparticles for cancer therapy. Nanomaterials
(Basel) 8:170. https://doi.org/10.3390/nano8030170
A. Pandey
Lysik MA, Wu-Pong S (2003) Innovations in oligonucleotide drug delivery. J Pharm Sci
92:1559–1573. https://doi.org/10.1002/jps.10399
Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, Anraku M, Hirayama
F, Uekama K, Otagiri M (2010) Evaluation of carboxymethyl-β-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. Int J
Pharm 397:1–8. https://doi.org/10.1016/j.ijpharm.2010.06.018
Maestrelli F, González-Rodríguez ML, Rabasco AM, Mura P (2005) Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug
delivery. Int J Pharm 298:55–67. https://doi.org/10.1016/j.ijpharm.2005.03.033
Maestrelli F, Garcia-Fuentes M, Mura P, Alonso MJ (2006) A new drug nanocarrier consisting
of chitosan and hydroxyl propyl cyclodextrin. Eur J Pharm Biopharm 63:79–86. https://doi.
org/10.1016/j.ejpb.2005.12.006
Maestrelli F, González-Rodríguez ML, Rabasco AM, Ghelardini C, Mura P (2010) New “drugin cyclodextrin-in deformable liposomes” formulations to improve the therapeutic efficacy of
local anaesthetics. Int J Pharm 395:222–231. https://doi.org/10.1016/j.ijpharm.2010.05.046
Mahmoud AA, El-Feky GS, Kamel R, Awad GEA (2011) Chitosan/sulfobutylether-β-cyclodextrin
nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 413:229–236.
https://doi.org/10.1016/j.ijpharm.2011.04.031
McCormack B, Gregoriadis G (1994a) Drugs-in-cyclodextrins-in liposomes: a novel concept in
drug delivery. Int J Pharm 112:249–258. https://doi.org/10.1016/0378-5173(94)90361-1
McCormack B, Gregoriadis G (1994b) Entrapment of cyclodextrin-drug complexes into
liposomes: potential advantages in drug delivery. J Drug Target 2:449–454. https://doi.
org/10.3109/10611869408996821
McCormack B, Gregoriadis G (1996) Comparative studies of the fate of free and liposomeentrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats:
implications in drug delivery. Biochim Biophys Acta 1291:237–244. https://doi.org/10.1016/
S0304-4165(96)00096-7
Memişoğlu E, Bochot A, Özalp M, Sen M, Duchêne D, Hincal A (2003) Direct formation of
nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res 20:117–125.
https://doi.org/10.1023/A:1022263111961
Bilensoy E, Vural I, Bochot A, Renoir JM, Duchene D, Hincal AA (2005) Tamoxifen citrate loaded
amphiphilic β-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J Control
Release 104:489–496. https://doi.org/10.1016/j.jconrel.2005.03.006
Méndez-Ardoy A, Guilloteau N, Di Giorgio C, Vierling P, Santoyo-González F, Ortiz Mellet C,
García Fernández JM (2011) β-cyclodextrin-based polycationic amphiphilic “click” clusters:
effect of structural modifications in their DNA complexing and delivery properties. J Org Chem
76:5882–5894. https://doi.org/10.1021/jo2007785
Mennini N, Cirri M, Maestrelli F, Mura P (2016) Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin:
effect of cyclodextrin complexation. Int J Pharm 515:684–691. https://doi.org/10.1016/j.
ijpharm.2016.11.013
Merkus FWHM, Verhoef JC, Romeijn SG, Schipper NGM (1991) Absorption enhancing effect of
cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588–592. https://doi.
org/10.1023/A:1015896405389
Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, Van Der Kuy PHM, Hermens WAJJ,
Schipper NGM (1999) Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36:41–57.
https://doi.org/10.1016/S0169-409X(98)00054-4
Messner M, Kurkov SV, Jansook P, Loftsson T (2010) Self-assembled cyclodextrin aggregates and
nanoparticles. Int J Pharm 387:199–208. https://doi.org/10.1016/j.ijpharm.2009.11.035
Mrówczyński R, Jędrzak A, Szutkowski K, Grześkowiak BF, Coy E, Markiewicz R, Jesionowski T,
Jurga S (2018) Cyclodextrin-based magnetic nanoparticles for cancer therapy. Nanomaterials
(Basel) 8:170. https://doi.org/10.3390/nano8030170
A. Pandey